Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care therapies (investigator’s choice), resulting in an ...
Herpes is one of the most common viral infections in the world, yet it remains widely misunderstood. Caused by the herpes ...
Sarah* will never forget the moment her life split in two: the time when she was blissfully unaware, and the "after", when ...
Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results